Reviewer’s report

Title: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

Version: 2 Date: 21 November 2012

Reviewer: Wasia Rizwani

Reviewer’s report:

The manuscript titled “MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1” by Olsson, H et al is a systematic study on a population with stage T1 specific bladder cancer patients. They demonstrate that neither MDM2 SNP309 polymorphism nor p53 mutations are associated with worse prognosis in patients with T1 bladder carcinoma. However, patients with abnormal p16 expression and mutated p53 gene showed increased rate of bladder cancer and shorter time to cancer progression.

Minor essential revisions.
- Does abnormal p16 expression mean over expression of p16 or less expression? Please clarify.
- Table 2 includes information on other antibodies also that were not employed in this study. These can be removed from the table or information on p53 and p16 can be included in the methods section itself.
- Please include references to methodologies used.
- Some references related to studies on p53 mutations and p16 expression in bladder cancer that may be included are:

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a
statistician.

Declaration of competing interests:
I declare that I have no competing interests.